Chronic kidney disease (CKD) is a “silent condition” that affects 37 million people in the United States.1 90% of Americans with CKD don’t know they have it, including almost half of those with advanced disease approaching end-stage renal disease (ESRD).2
CKD is a disease-multiplier and for many is associated with underlying comorbid conditions that increase both complications and costs.
Optum, OptumLabs®, and the National Kidney Foundation (NKF) engaged in a collaborative study to identify the predictors of late-stage kidney disease and assist in early intervention to slow its progression.
Incorporating results from both machine learning and industry research, the study aims to help health plans integrate best practice care management and identify areas to reduce medical spend.
Hear the joint research panel discuss the study insights and potential implications, including:
- Medical cost benefit of early CKD diagnosis
- Factors that suggest progression risk
- Policy context that increases the importance of earlier diagnosis
- Therapeutic opportunities in CKD